A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. Business Immunovant is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402, a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. We believe that FcRn inhibition has broad therapeutic and commercial potential to address IgG-mediated autoimmune diseases in several therapeutic areas, including but not limited to, endocrinology, neurology, rheumatology and dermatology.
| Metric | TTM | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 0 | - | - | 0 |
| Net Income | -464M | -259M | -211M | -157M |
| EPS | $-2.67 | $-1.88 | $-1.71 | $-1.43 |
| Free Cash Flow | -423M | -215M | -188M | -106M |
| ROIC | 0.0% | -52.9% | -58.2% | -33.4% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | 0 | -234M | -203M | -157M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -47.1% | -52.9% | -58.2% | -33.4% |
| Shares Outstanding | 204M | 138M | 123M | 110M |
| Metric | 2022 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 102M | 160M | 213M | 408M |
| SG&A | 54M | 48M | 57M | 79M |
| EBIT | -157M | -203M | -234M | 0 |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -157M | -211M | -259M | -464M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -33.4% | -58.2% | -52.9% | 0.0% |
| ROE | -33.4% | -58.2% | -52.9% | -47.1% |
| ROA | -30.4% | -52.0% | -48.4% | -44.1% |
| Cash Flow | ||||
| Op. Cash Flow | -106M | -188M | -214M | -423M |
| Free Cash Flow | -106M | -188M | -215M | -423M |
| Owner Earnings | -140M | -221M | -256M | -480M |
| CapEx | 254K | 197K | 360K | 201K |
| Maint. CapEx | 126K | 193K | 231K | 422K |
| Growth CapEx | 128K | 4K | 129K | 0 |
| D&A | 126K | 193K | 231K | 422K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 34M | 32M | 41M | 56M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -985M | -752M | -1.3B | -2.0B |
| Cash & Equiv. | 494M | 377M | 635M | 2.0B |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | N/A | -26.8 | -9.4 | -9.4 |
| Equity | 470M | 362M | 618M | 986M |
| Total Assets | 516M | 406M | 666M | 1.1B |
| Total Liabilities | 46M | 43M | 49M | 66M |
| Intangibles | N/A | N/A | N/A | N/A |
| Retained Earnings | -355M | -566M | -826M | -1.6B |
| Working Capital | 468M | 361M | 617M | 977M |
| Current Assets | 513M | 404M | 666M | 1.0B |
| Current Liabilities | 45M | 43M | 49M | 66M |
| Per Share Data | ||||
| EPS | -1.43 | -1.71 | -1.88 | -2.67 |
| Owner EPS | -1.28 | -1.79 | -1.85 | -2.36 |
| Book Value | 4.29 | 2.94 | 4.48 | 4.85 |
| Cash Flow/Share | -0.97 | -1.53 | -1.55 | -2.28 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 109.6M | 123.4M | 137.9M | 203.5M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -9.4 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | 1.3 | 5.3 | 7.2 | 5.2 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | -17.3% | -9.9% | -4.8% | -8.3% |
| Market Cap | 614M | 1.9B | 4.5B | 5.1B |
| Avg. Price | 9.49 | 9.63 | 28.46 | 25.12 |
| Year-End Price | 5.60 | 15.50 | 32.31 | 25.12 |
Immunovant, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Immunovant, Inc. (IMVT) has a 5-year average return on invested capital (ROIC) of -48.2%. This is below average and may indicate limited pricing power.
Immunovant, Inc. (IMVT) has a market capitalization of $5.1B. It is classified as a mid-cap stock.
Immunovant, Inc. (IMVT) does not currently pay a regular dividend.
Immunovant, Inc. (IMVT) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Immunovant, Inc. (IMVT) generated $-215 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Immunovant, Inc. (IMVT) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Immunovant, Inc. (IMVT) reported earnings per share (EPS) of $-1.88 in its most recent fiscal year.
Immunovant, Inc. (IMVT) has a return on equity (ROE) of -52.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Immunovant, Inc. (IMVT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Immunovant, Inc. (IMVT) has a book value per share of $4.48, based on its most recent annual SEC filing.